

<b>Reference:</b>	FOI.1505.19
<b>Subject:</b>	Bone metastases
<b>Date of Request:</b>	2 September 2019

**Requested**

1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.
2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
  - disodium pamidronate (Aredia)
  - ibandronic acid or ibandronate (Bondronat)
  - sodium clodronate (Bonefos, Clasteon, Loron)
  - zoledronic acid or zoledronate (Zometa)
  - denosumab (Xgeva)
3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;
  - disodium pamidronate (Aredia)
  - ibandronic acid or ibandronate (Bondronat)
  - sodium clodronate (Bonefos, Clasteon, Loron)
  - zoledronic acid or zoledronate (Zometa)
4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
  - disodium pamidronate (Aredia)
  - ibandronic acid or ibandronate (Bondronat)
  - sodium clodronate (Bonefos, Clasteon, Loron)
  - zoledronic acid or zoledronate (Zometa)
  - denosumab (Xgeva)
6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
  - disodium pamidronate (Aredia)
  - ibandronic acid or ibandronate (Bondronat)
  - sodium clodronate (Bonefos, Clasteon, Loron)
  - zoledronic acid or zoledronate (Zometa)
  - denosumab (Xgeva)

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the numbers of patients currently being treated, as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare team, who hold a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records to establish the type of therapies being used to treat the patients. It is estimated that conducting this search would take longer than the 18 hour ‘appropriate limit’ as stated within the Act.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act, the UHB has an obligation to provide advice and assistance.

The UHB is unable to identify what the treatment was for but does provide, within the table below, the number of patients that received the following treatments between March and August 2019.

<b>Treatment</b>	<b>Number</b>
Disodium pamidronate (Aredia)	13
Ibandronic acid or ibandronate (Bondronat)	14
Sodium clodronate (Bonafos, Clasteon, Loron)	6
Zoledronic acid or zoledronate (Zometa)	240
Denosumab (Xgeva)	147

For further information, we would recommend that you redirect your request to the Freedom of Information Team in SBUHB who may be able to help you with your enquiry:-

[FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk) or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.